MedTrace Logo

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

NCT04836832 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-06-07

No results posted yet for this study

Summary

This phase Ib/II trial studies the side effects of acalabrutinib and duvelisib and how well they work in treating patients with indolent non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Acalabrutinib inhibits a signaling molecule called Bruton tyrosine kinase and blocks cancer cell proliferation, growth, and survival. Duvelisib is designed to block a protein called PI3 kinase in order to stop cancer growth and cause changes in the immune system that may allow the immune system to better act against cancer cells. Giving acalabrutinib and duvelisib together may work better to block cancer growth than therapy of either drug alone.

Conditions

  • Recurrent Follicular Lymphoma
  • Recurrent Marginal Zone Lymphoma
  • Recurrent Nodal Marginal Zone Lymphoma
  • Recurrent Splenic Marginal Zone Lymphoma
  • Refractory Follicular Lymphoma
  • Refractory Indolent Non-Hodgkin Lymphoma
  • Refractory Marginal Zone Lymphoma
  • Refractory Nodal Marginal Zone Lymphoma
  • Refractory Splenic Marginal Zone Lymphoma

Interventions

DRUG

Acalabrutinib

Given PO

DRUG

Duvelisib

Given PO

Sponsors & Collaborators

  • Narendranath Epperla

    lead OTHER

Principal Investigators

  • Narendranath Epperla, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-12-31
Completion
2024-12-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04836832 on ClinicalTrials.gov